Plasticell completes £1.4m equity financing round
Plasticell, a biotechnology company specialising in cell and gene therapy research, has completed an equity financing round raising a total of £1.4 million.
The company, based at the Stevenage Bioscience Catalyst, specialises in using massively parallel screening technologies to discover, develop and optimise manufacturing of high value cell therapies derived from stem cells.
Its award-winning combinatorial screening technology, CombiCult®, can be applied to any cell culture process including biopharmaceutical production, as well as cell and gene therapy manufacturing.
Plasticell’s lead therapeutic programme is in the expansion of hematopoietic stem cells derived from bone marrow and cord blood, for both cell and gene therapy applications.
The company has previously announced securing government grants of over £2 million to develop GMP manufacturing and complete pre-clinical work streams for this therapy.
As well as advancing this therapy towards the clinic, the financing will be deployed to progress earlier-stage programmes in allogeneic immunotherapies.
Plasticell collaborates with universities and industry partners to facilitate discovery and improve product manufacturing in a variety of high value areas such as cell therapy, gene therapy, cancer immunotherapy and drug discovery.
Plasticell chairman and founder Dr Yen Choo was a founder and chief scientists at Gendaq (acquired by Sangamo Biosciences), a biotech company that developed the zinc finger technology now used for gene editing.
Previously he was a staff scientist at the MRC Laboratory of Molecular Biology, Cambridge, where he pioneered the engineering of protein-DNA interactions using combinatorial methods under Nobel laureate Sir Aaron Klug.